ADVERTISEMENT
MRSI Parameters Can Predict Early Recurrence Postsurgery in Prostate Cancer
Findings from a study of patients with nonmetastatic prostate cancer suggest that magnetic resonance spectroscopy imaging (MRSI) parameters can help accurately predict the risk for biochemical recurrence (BCR) after radical prostatectomy (Prague Med Rep. 2019;120[2-3]:74-83).
Mehdi Kardoust Parizi, MD, Department of Urology, Tehran University of Medical Sciences, Shariati Hospital, Iran, and colleagues conducted the prospective study with the purpose of assessing the role of MRSI parameters in early prediction of BCR after radical prostatectomy in this patient population.
A total of 60 patients with nonmetastatic prostate cancer who had radical prostatectomies after MRSI assessment between November 2010 and March 2012 were included in the study. Dr Parizi et al collected demographic, clinicopathologic, MRI staging, MRSI parameters, and postsurgery serum prostate-specific antigen (PSA) data, and evaluated the link between potential prognosticators and early BCR (<12 months postsurgery) using univariate and multivariate Cox regression analyses.
According to univariate Cox regression, preoperative serum PSA (hazard ratio [HR], 1.016; P = .003), surgical Gleason score >7 (HR, 5.034; P = .006), and MRSI risk score (HR, 4.061; P = .0001) demonstrated an association with early BCR.
Similarly, multivariate models showed that preoperative serum PSA (HR, 1.012; P = .046), surgical Gleason score >7 (HR, 4.196; P = .017), and MRSI risk score (HR, 3.256; P = .013) were tied to early BCR.
Of note, Dr Parizi and colleagues found that the greatest AUC (area under the curve) was related to MRSI risk score (AUC, 0.733). In addition, the AUC of the multivariate model was 0.776.
“These parameters can improve the accuracy of predictive nomograms to assess the risk of BCR after [radical prostatectomy],” they concluded.—Hina Porcelli
